Amgen Inc. — Form 10-Q Summary
Business context and reporting period
Amgen is a global biotechnology company focused on human therapeutics and reports as one business segment. This unaudited filing covers the quarter and six months ended June 30, 2017; comparisons are with the corresponding 2016 periods. Interim results may not indicate full-year performance.
Financial performance and position
| Metric | Q2 2017 | Q2 2016 | Six months 2017 | Six months 2016 |
|---|---|---|---|---|
| Total revenue | $5.810B | $5.688B | $11.274B | $11.215B |
| Operating income | $2.698B | $2.380B | $5.289B | $4.782B |
| Net income | $2.151B | $1.870B | $4.222B | $3.770B |
| Diluted EPS | $2.91 | $2.47 | $5.71 | $4.97 |
- Q2 revenue rose 2%; operating income rose 13%, net income 15%, and diluted EPS 18%. For the first half, revenue rose 1%, operating income 11%, net income 12%, and diluted EPS 15%.
- Operating margin was approximately 46.4% in Q2 versus 41.9% in Q2 2016; first-half margin was approximately 46.9% versus 42.6%. Improved margins reflect lower operating expenses, including transformation savings and lower royalty costs.
- Q2 product sales increased 2%. Growth in Prolia, Sensipar/Mimpara, Repatha and KYPROLIS was partly offset by declines in ENBREL, Neulasta, EPOGEN and NEUPOGEN. ENBREL sales fell 8% and EPOGEN 11% in the first half; Prolia rose 17% and Sensipar/Mimpara 12%.
- Six-month operating cash flow was $4.711B, compared with $4.592B. Investing cash outflow was $1.970B, versus $5.047B; financing cash outflow was $3.353B, versus $1.059B. Cash and cash equivalents declined $612M to $2.629B.
- At June 30, cash, cash equivalents and marketable securities totaled $39.227B. Total debt carrying value was $35.062B, including $33.603B long-term debt and $1.459B current debt. Total debt increased from $34.596B at year-end 2016. The company issued $3.5B of notes in May and repaid several 2017 maturities.
- Stockholders’ equity was $31.722B, up from $29.875B at December 31, 2016. First-half dividends paid were $1.693B and share repurchases were $1.562B; $2.5B remained authorized for repurchases.
Material changes, outlook and commentary
- Management attributed expense reductions to transformation and process-improvement efforts and reported approximately $1.3B of savings since 2014, reinvested in launches, clinical programs and business development. Restructuring charges incurred to date totaled $760M; estimated total pre-tax charges remain $800M–$900M.
- Management expected operating expenses to be higher in the second half of 2017 because of expense timing, and estimated 2017 capital spending of approximately $700M. The filing does not provide a numerical full-year revenue or EPS forecast.
- Management said existing funds, operating cash flow and financing access should meet working-capital, capital-spending, debt-service and planned shareholder-return needs. About $37.4B of cash, cash equivalents and marketable securities was generated in foreign tax jurisdictions and intended to remain invested outside the United States; repatriation could incur additional U.S. income taxes.
- The April 2017 Novartis migraine collaboration gives Amgen U.S. product sales and manufacturing responsibilities for Aimovig, with shared U.S. commercialization costs and royalties payable to Novartis; Novartis has exclusive commercial rights outside the United States and Japan. Potential milestone payments to Amgen could exceed $400M if specified events and thresholds are achieved.
- Key product and development uncertainty: an imbalance in adjudicated serious cardiovascular adverse events was observed in the EVENITY ARCH study, and the FDA issued a Complete Response Letter in July 2017. Amgen did not expect U.S. approval in 2017. The filing also describes regulatory reviews and development updates for other products, including Repatha, Aimovig and biosimilar candidates.
Risks, contingencies and unusual items
- An IRS Revenue Agent Report for 2010–2012 proposed significant adjustments, primarily concerning profit allocation between U.S. and Puerto Rico entities. Amgen contests the proposed adjustments; an unfavorable resolution could materially affect results and cash flows. The administrative appeals process was not expected to conclude within 12 months.
- Amgen faces patent, biosimilar, product-marketing and other legal proceedings. The filing says matters generally had not advanced enough to estimate a range of possible losses; an adverse determination in one or more could materially affect results, financial position or cash flows.
- Amgen performs most commercial manufacturing in Puerto Rico. Puerto Rico’s fiscal and debt crisis could affect utilities, services, taxes, workforce availability or operating costs, creating a supply-continuity risk.
- Competition and pricing pressure weigh on certain established products, including ENBREL, EPOGEN and Neulasta; the Sensipar U.S. composition-of-matter patent expires in March 2018. The filing also identifies risks from biosimilar entry and evolving regulatory requirements.
Important facts for investors to verify
- Whether growth in key products, particularly Prolia, Sensipar, Repatha and KYPROLIS, can offset declines and competitive pressure in older products.
- Developments in the IRS dispute, the potential cash or earnings impact, and whether recorded tax reserves remain adequate.
- EVENITY’s cardiovascular safety signal and regulatory path, as well as the status of other key clinical and regulatory milestones.
- Puerto Rico manufacturing continuity and any effects of the territory’s fiscal crisis on supply, costs or operations.
- Debt levels, interest costs and the sustainability of dividends and repurchases alongside investment and debt-service needs.